{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T13:12:01Z","timestamp":1768569121163,"version":"3.49.0"},"posted":{"date-parts":[[2025,7,24]]},"group-title":"Neurology","reference-count":25,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.medrxiv.org\/about\/FAQ#license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2025,7,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To evaluate the predictive utility of baseline plasma biomarkers and neuropsychological measures in identifying cognitively unimpaired older adults at risk of cognitive and functional decline over five years.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The clinical and biological heterogeneity observed in Alzheimer\u2019s disease (AD) complicates design of trials and the identification of appropriate participants. Identifying practical tools to define more homogenous subgroups could enhance clinical trial enrichment and improve early detection.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We analyzed data from the Anti-Amyloid Treatment in Asymptomatic Alzheimer\u2019s Disease (A4) trial and its companion Evaluation of Amyloid Risk and Neurodegeneration (LEARN) observational study. The sample included 866 cognitively unimpaired, amyloid-positive individuals from the A4 trial (comprising participants randomized to receive Solanezumab or placebo) and 343 cognitively unimpaired, amyloid-negative individuals from LEARN. Cognitive\/functional decline was defined as an increase of \u22650.5 in Clinical Dementia Rating\u2013Global Score (CDR-GS) during a 240-week period. Using multiple logistic regression models, we evaluated the predictive value of demographic variables, APOE4 status, amyloid PET SUVR, plasma P-tau217, and Alzheimer\u2019s Disease Cooperative Study\u2013Preclinical Alzheimer\u2019s Cognitive Composite (ADCS-PACC) in three groups: A4-Solanezumab, A4-placebo and LEARN. In a sub-study including 656 participants with available data, we assessed the incremental value of additional plasma biomarkers (A\u03b242\/A\u03b240 ratio, GFAP, and NfL).<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Both plasma P-tau217 and ADCS-PACC significantly improved predictive performance over a base model with demographics and APOE4. The full model combining all predictor variables yielded the highest AUCs across A4 Solanezumab (0.80 \u00b1 0.06), A4 Placebo (0.80 \u00b1 0.06), and LEARN (0.78 \u00b1 0.08). Adding other plasma biomarkers yielded small but consistent improvements in AUC (1\u20133%).<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Plasma P-tau217 and ADCS-PACC, individually and in combination, improved prediction of cognitive\/functional decline in asymptomatic older adults. Predictive models incorporating these scalable and non-invasive measures improved clinical trial enrichment and earlier identification of at-risk individuals preclinical AD.<\/jats:p>\n                <\/jats:sec>","DOI":"10.1101\/2025.07.22.25332015","type":"posted-content","created":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T20:55:15Z","timestamp":1753390515000},"source":"Crossref","is-referenced-by-count":1,"title":["Incremental Value of Plasma Biomarkers in Predicting Clinical Decline Among Cognitively Unimpaired Older Adults: Results from the A4 trial"],"prefix":"10.64898","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1585-3909","authenticated-orcid":false,"given":"Babak","family":"Khorsand","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elham","family":"Ghanbarian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Rabin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seyed Ahmad","family":"Sajjadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Ezzati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"issue":"5","key":"2025072607300539000_2025.07.22.25332015v1.1","doi-asserted-by":"crossref","first-page":"3708","DOI":"10.1002\/alz.13809","article-title":"2024 Alzheimer\u2019s disease facts and figures","volume":"20","year":"2024","journal-title":"Alzheimer\u2019s & Dementia"},{"key":"2025072607300539000_2025.07.22.25332015v1.2","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-019-0333-5"},{"issue":"1","key":"2025072607300539000_2025.07.22.25332015v1.3","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3233\/JAD-190822","article-title":"Machine learning predictive models can improve efficacy of clinical trials for Alzheimer\u2019s disease","volume":"74","year":"2020","journal-title":"Journal of Alzheimer\u2019s Disease"},{"issue":"1","key":"2025072607300539000_2025.07.22.25332015v1.4","first-page":"e12223","article-title":"Application of predictive models in boosting power of Alzheimer\u2019s disease clinical trials: A post hoc analysis of phase 3 solanezumab trials","volume":"8","year":"2022","journal-title":"Alzheimer\u2019s & Dementia: Translational Research & Clinical Interventions"},{"issue":"8","key":"2025072607300539000_2025.07.22.25332015v1.5","doi-asserted-by":"crossref","first-page":"e213490","DOI":"10.1212\/WNL.0000000000213490","article-title":"A Machine Learning Approach to Predict Cognitive Decline in Alzheimer Disease Clinical Trials","volume":"104","year":"2025","journal-title":"Neurology"},{"issue":"4","key":"2025072607300539000_2025.07.22.25332015v1.6","doi-asserted-by":"crossref","first-page":"850","DOI":"10.3390\/biomedicines10040850","article-title":"Development of Alzheimer\u2019s disease biomarkers: From CSF-to blood-based biomarkers","volume":"10","year":"2022","journal-title":"Biomedicines"},{"issue":"4","key":"2025072607300539000_2025.07.22.25332015v1.7","doi-asserted-by":"crossref","first-page":"831","DOI":"10.14283\/jpad.2024.124","article-title":"Relationship between Plasma P-Tau217 and Amyloid PET in Racial and Ethnic Underrepresented Groups (RE-URG) Compared with Non RE-URG in LEARN and A4","volume":"11","year":"2024","journal-title":"The Journal of Prevention of Alzheimer\u2019s Disease"},{"issue":"12","key":"2025072607300539000_2025.07.22.25332015v1.8","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1002\/alz.12756","article-title":"The Alzheimer\u2019s Association appropriate use recommendations for blood biomarkers in Alzheimer\u2019s disease","volume":"18","year":"2022","journal-title":"Alzheimer\u2019s & Dementia"},{"issue":"8","key":"2025072607300539000_2025.07.22.25332015v1.9","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1001\/jamaneurol.2014.803","article-title":"The preclinical Alzheimer cognitive composite: measuring amyloid-related decline","volume":"71","year":"2014","journal-title":"JAMA neurology"},{"key":"2025072607300539000_2025.07.22.25332015v1.10","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3007941"},{"key":"2025072607300539000_2025.07.22.25332015v1.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2305032"},{"key":"2025072607300539000_2025.07.22.25332015v1.12","doi-asserted-by":"crossref","unstructured":"Schmidt, K. , Clinical dementia rating scale, in Encyclopedia of quality of life and well-being research. 2021, Springer. p. 1\u20135.","DOI":"10.1007\/978-3-319-69909-7_690-2"},{"issue":"1","key":"2025072607300539000_2025.07.22.25332015v1.13","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3233\/JAD-221118","article-title":"Evaluation of blood-based plasma biomarkers as potential markers of amyloid burden in preclinical Alzheimer\u2019s disease","volume":"92","year":"2023","journal-title":"Journal of Alzheimer\u2019s Disease"},{"key":"2025072607300539000_2025.07.22.25332015v1.14","doi-asserted-by":"publisher","DOI":"10.1001\/JAMA.2020.12134"},{"key":"2025072607300539000_2025.07.22.25332015v1.15","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-020-00923-z"},{"key":"2025072607300539000_2025.07.22.25332015v1.16","first-page":"1","article-title":"Plasma neurofilament light and phosphorylated tau 181 as biomarkers of Alzheimer\u2019s disease pathology and clinical disease progression","volume":"13","year":"2021","journal-title":"Alzheimer\u2019s research & therapy"},{"issue":"1","key":"2025072607300539000_2025.07.22.25332015v1.17","doi-asserted-by":"crossref","first-page":"231","DOI":"10.3233\/JAD-230620","article-title":"Plasma biomarkers as predictors of progression to dementia in individuals with mild cognitive impairment","volume":"98","year":"2024","journal-title":"Journal of Alzheimer\u2019s Disease"},{"key":"2025072607300539000_2025.07.22.25332015v1.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2017.02.003"},{"key":"2025072607300539000_2025.07.22.25332015v1.19","doi-asserted-by":"publisher","DOI":"10.1038\/s41583-019-0240-3"},{"issue":"5","key":"2025072607300539000_2025.07.22.25332015v1.20","first-page":"e662","article-title":"Association of \u03b2-amyloid level, clinical progression, and longitudinal cognitive change in normal older individuals","volume":"96","year":"2021","journal-title":"Neurology"},{"issue":"2","key":"2025072607300539000_2025.07.22.25332015v1.21","doi-asserted-by":"crossref","first-page":"255","DOI":"10.14283\/jpad.2022.17","article-title":"Sensitivity of the preclinical Alzheimer\u2019s cognitive composite (PACC), PACC5, and repeatable battery for neuropsychological status (RBANS) to amyloid status in preclinical Alzheimer\u2019s disease-atabecestat phase 2b\/3 EARLY clinical trial","volume":"9","year":"2022","journal-title":"The journal of prevention of Alzheimer\u2019s disease"},{"issue":"6","key":"2025072607300539000_2025.07.22.25332015v1.22","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1080\/13803395.2019.1593949","article-title":"Sensitivity of a Preclinical Alzheimer\u2019s Cognitive Composite (PACC) to amyloid \u03b2 load in preclinical Alzheimer\u2019s disease","volume":"41","year":"2019","journal-title":"Journal of clinical and experimental neuropsychology"},{"key":"2025072607300539000_2025.07.22.25332015v1.23","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-019-0546-4"},{"issue":"1","key":"2025072607300539000_2025.07.22.25332015v1.24","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s13195-024-01478-9","article-title":"Comparison of plasma and neuroimaging biomarkers to predict cognitive decline in non-demented memory clinic patients","volume":"16","year":"2024","journal-title":"Alzheimer\u2019s Research & Therapy"},{"issue":"3","key":"2025072607300539000_2025.07.22.25332015v1.25","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/alz.12745","article-title":"AmyloidLbeta misfolding and GFAP predict risk of clinical Alzheimer\u2019s disease diagnosis within 17 years","volume":"19","year":"2023","journal-title":"Alzheimer\u2019s & Dementia"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2025.07.22.25332015","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T20:41:21Z","timestamp":1768509681000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2025.07.22.25332015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,24]]},"references-count":25,"URL":"https:\/\/doi.org\/10.1101\/2025.07.22.25332015","relation":{},"subject":[],"published":{"date-parts":[[2025,7,24]]},"subtype":"preprint"}}